These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia. Chiu W; Pullon H; Woon ST; Oei P; The R; Ameratunga R Pathology; 2010 Jan; 42(1):82-4. PubMed ID: 20025486 [No Abstract] [Full Text] [Related]
7. [Prognostic factors in multiple myeloma]. Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219 [No Abstract] [Full Text] [Related]
8. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534 [TBL] [Abstract][Full Text] [Related]
9. Correlation of abnormal immunoglobulin with clinical features of myeloma. Arch Intern Med; 1975 Jan; 135(1):46-52. PubMed ID: 1111470 [TBL] [Abstract][Full Text] [Related]
10. [The effect of alkylating cytostatics on the development of secondary malignant tumors]. Galajda P; Donner L Vnitr Lek; 1984 Aug; 30(8):756-63. PubMed ID: 6506498 [No Abstract] [Full Text] [Related]
11. [Combined cytostatic therapy of plasmacytoma]. Albert P; Zsuzsa M Orv Hetil; 1977 Jul; 118(31):1855-6. PubMed ID: 887257 [No Abstract] [Full Text] [Related]
12. Letter: Variety in general practice. Jacobs P; Dubovsky D; King HS S Afr Med J; 1975 Apr; 49(16):650-1. PubMed ID: 49083 [No Abstract] [Full Text] [Related]